natgillin/translations-raw huggingface dataset:
Depending on the treated joint, you may have to wear a brace. 
Morda boste morali uporabljati opornico, odvisno od zdravljenega sklepa.
Spherox 10-70 spheroids/cm2 implantation suspension spheroids of human autologous matrix-associated chondrocytes 
Spherox 10-70 sferoidov/cm2 suspenzija za implantacijo sferoidi humanih avtolognih, na matriks nanesenih hondrocitov
Injury, poisoning and procedural complications 
Poškodbe, zastrupitve in zapleti pri posegih občasni hipertrofija, delaminacija presadka
below: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare 
Neželeni učinki, povezani z zdravilom Spherox, so prikazani v spodnji preglednici 1 glede na klasifikacijo organskih sistemov in pogostnost: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10),
Syringe 
ZDRAVILA
KOOS (Knee Injury and Osteoarthritis Outcome Score) after 12, 24, 36, 48 and 60 months compared to before treatment could be observed. 
Pri vseh 3 skupinah odmerkov je bilo po 12, 24, 36, 48 in 60 mesecih v primerjavi z obdobjem pred zdravljenjem opaziti znatno izboljšanje (α < 0,05) glede na vprašalnik
NAME OF THE MEDICINAL PRODUCT Spherox 10-70 spheroids/cm2 implantation suspension spheroids of human autologous matrix-associated chondrocytes 
Navodilo za uporabo Spherox 10-70 sferoidov/cm2 suspenzija za implantacijo sferoidi humanih avtolognih, na matriks nanesenih hondrocitov
Elderly 
OVOJNINAH
• muscle weakness 
• mišična oslabelost;
Graft delamination 
Injekcijska brizga:
• wound-related complication 
• zaplet, povezan z rano;
Spherox has been analysed in a prospective, randomized, uncontrolled open-label, multicentre Phase II clinical study including 75 patients with focal cartilage defects (ICRS grade III or IV) in the knee with a defect size of 4-10 cm2. 
Zdravilo Spherox je bilo analizirano v prospektivni randomizirani nekontrolirani odprti multicentrični klinični študiji II.
What Spherox looks like and contents of the package 
Izgled zdravila Spherox in vsebina pakiranja Suspenzija za implantacijo.
• ligament disorder 
• vnetje tetive;
Hypertrophy, Graft delamination 
omedlevica, povišana telesna temperatura);
• scar tissue pain 
• bolečina brazgotinastega tkiva.
What Spherox contains 
Spherox,
• SOC General disorders and administration site conditions: pain (common), gait disturbance (common), discomfort (uncommon) 
• Organski sistem (SOC) Splošne težave in spremembe na mestu aplikacije: bolečina (pogosti),
• Prescriber checklist 
• kontrolni seznam za zdravnika, ki predpiše zdravilo, ter
Application system co.fix 150 mm: EXP {DD month YYYY} at {hours} CET 
{1 ali 2} sistem/-a za aplikacijo co.fix 150 mm v sterilni tubi.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGINGUNITS Application system co.fix 150 mm or 
Če je primarna ovojnina sistem za aplikacijo co.fix 150 mm
Adverse Reaction 
Neželeni učinek
11 July 2014 
11. julij 2014
Article 34 of Directive 2001/82/EC, as amended 
Člen 34 Direktive 2001/82/ES, kakor je bila spremenjena.
The Committee appointed B. Urbain as rapporteur and C. Muñoz Madero as co-rapporteur. 
Odbor je za poročevalca imenoval B. Urbaina, za soporočevalca pa C. Muñoz Madera.
The final opinion was converted into a Decision by the European Commission on 11 July 2014. 
Končno mnenje je bilo 11. julija 2014 spremenjeno v Odločbo Evropske komisije.
The referral procedure started on 10 October 2012. 
Napotitveni postopek se je začel 10. oktobra 2012.
Veterinary Medicines Division 
Oddelek za veterinarsko medicino
Written explanations were provided by the marketing authorisation holders on 10 September 2013 and 10 February 2014. 
Imetniki dovoljenj za promet z zdravilom so 10. septembra 2013 in 10. februarja 2014 predložili pisna pojasnila.
The Committee adopted a positive opinion by consensus on 10 April 2014. 
Odbor je 10. aprila 2014 soglasno sprejel pozitivno mnenje.
International non-proprietary name (INN): lincomycin and spectinomycin 
Mednarodno nelastniško ime (INN): linkomicin in spektinomicin
Due to divergent national decisions taken by Member States with respect to target species, indications, posology and withdrawal periods concerning the authorisations of Linco-Spectin 100 and its associated names, on 28 September 2012 Belgium referred the issue to the CVMP under Article 34(1) of Directive 2001/82/EC, in order to resolve divergences in the nationally authorised product information across the European Union. 
Zaradi različnih nacionalnih odločitev, ki so jih sprejele države članice glede ciljnih vrst, indikacij, odmerjanja in karenc v zvezi z odobritvijo zdravila Linco-Spectin 100 in povezanih imen, je 28. septembra 2012 Belgija napotila zadevo Odboru CVMP v skladu s členom 34(1) Direktive 2001/82/ES, da razreši neskladja med nacionalno odobrenimi informacijami o zdravilu po vsej Evropski uniji.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended summary of product characteristics, labelling and package leaflet in Annex III. 
Seznam zadevnih imen zdravila je v Prilogi I. Znanstveni zaključki skupaj s spremenjenim povzetkom glavnih značilnosti zdravila so v Prilogi II, označevanje in navodilo za uporabo pa sta v Prilogi III.
Based on the evaluation of the currently available data, the CVMP considered that the benefit-risk profile of of Linco-Spectin 100 and its associated names remains positive, subject to variation of the marketing authorisations in accordance with the recommended product information. 
Na podlagi ocene trenutno razpoložljivih podatkov je Odbor CVMP presodil, da razmerje med tveganji in koristmi za zdravilo Linco-Spectin 100 in povezana imena ostaja pozitivno, ob upoštevanju spremembe dovoljenj za promet z zdravilom v skladu s priporočenimi informacijami o zdravilu.
Opinion following an Article 340F referral for Linco-Spectin 100 and associated names EMA/431244/2014 
Mnenje v zvezi z napotitvijo v skladu s členom 340F za zdravilo Linco-Spectin 100 in povezana imena EMA/431244/2014
Linco-Spectin 100 is a powder for oral solution containing 33.3 g lincomycin (as lincomycin hydrochloride) and 66.7 g spectinomycin (as spectinomycin sulphate) per 150 g pack. 
Zdravilo Linco-Spectin 100 je prašek za peroralno raztopino, ki vsebuje 33,3 g linkomicina (v obliki linkomicinijevega hidroklorida) in 66,7 g spektinomicina (v obliki spektinomicinijevega sulfata) na pakiranje 150 g. Linkomicin je linkozamidni antibiotik, zelo podoben makrolidnim antibiotikom in streptograminom B. Spektinomicin je razvrščen kot aminociklitolni antibiotik, soroden aminoglikozidom.
Opinion following an Article 341 referral for Linco-Spectin 100 and associated names 
za zdravilo Linco-Spectin 100 in povezana imena
Strength Pharmaceutical Form Route of Administration 
Jakost Farmacevtska oblika
This summary was last updated in 03-2016. 
Povzetek je bil nazadnje posodobljen 03-2016.
The European Commission granted a marketing authorisation valid throughout the European Union for TachoSil on 8 June 2004. 
Evropska komisija je dovoljenje za promet z zdravilom TachoSil, veljavno po vsej Evropski uniji, izdala 8. junija 2004.
TachoSil is used when standard techniques are not sufficient. 
Zdravilo TachoSil se uporablja, kadar standardne tehnike ne zadoščajo.
TachoSil fibrinogen / thrombin 
TachoSil fibrinogen/trombin
What measures are being taken to ensure the safe and effective use of TachoSil? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila TachoSil?
TachoSil is used in adults: 
TachoSil se uporablja pri odraslih:
The full EPAR for TachoSil can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The TachoSil patch is left in the body, where it dissolves and disappears completely. 
Obliž TachoSil ostane v telesu, kjer se popolnoma raztopi in izgine.
Other information about TachoSil 
Druge informacije o zdravilu TachoSil
This is a summary of the European public assessment report (EPAR) for TachoSil. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo TachoSil.
TachoSil has been studied in seven studies: 
Zdravilo TachoSil so proučevali v sedmih študijah:
For more information about treatment with TachoSil, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom TachoSil preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that TachoSil is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila TachoSil je bil pripravljen načrt obvladovanja tveganj.
TachoSil should only be used by an experienced surgeon. 
Zdravilo TachoSil lahko uporablja le izkušen kirurg.
The main measure of effectiveness was the number of patients whose bleeding had stopped after three minutes. 
Glavno merilo učinkovitosti je bilo število bolnikov, ki so prenehali krvaveti po treh minutah.
What benefit has TachoSil shown during the studies? 
Kakšne koristi je zdravilo TachoSil izkazalo med študijami?
Thrombin works by converting fibrinogen into smaller units called fibrin, which then stick together to form a local clot. 
Trombin deluje tako, da pretvarja fibrinogen v manjše enote, imenovane fibrin, ki se nato zlepljajo in tvorijo lokalni strdek.
The CHMP decided that TachoSil's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila TachoSil večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The first study looking at lung surgery patients was not sufficient to support the use of TachoSil in sealing tissue since very few patients in the study had any air leakage. 
Prva študija na bolnikih, operiranih na pljučih, ni zadoščala za podporo uporabe zdravila TachoSil za zapiranje tkiva, saj so pri zelo malo bolnikih iz študije zaznali kakršno koli uhajanje zraka.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for TachoSil. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What is the risk associated with TachoSil? 
Kakšna tveganja so povezana z zdravilom TachoSil?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for TachoSil, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
TachoSil should only be applied directly onto the treatment site so that it covers 1 to 2 cm beyond the edge of the wound. 
Zdravilo TachoSil se uporablja le neposredno na mestu zdravljenja, in sicer tako, da sega 1-2 cm preko robov rane.
In the first study, the average time until bleeding stopped was 3.9 minutes with TachoSil compared with 6.3 minutes with the argon beamer, and in the second study, these values were 3.6 and 5.0 minutes, respectively. 
V prvi študiji je bil povprečen čas, potreben za zaustavitev krvavitve, pri uporabi zdravila TachoSil 3,9 minut, ob uporabi argonskega plazemskega koagulatorja pa 6,3 minute, medtem ko so bile v drugi študiji te vrednosti 3,6 in 5,0 minut.
This way it prevents the cerebrospinal fluid from leaking. 
S tem prepreči prepuščanje cerebrospinalne tekočine.
The active substances in TachoSil, fibrinogen and thrombin, are proteins extracted from blood, which are involved in the natural clotting process. 
Zdravilni učinkovini v zdravilu TachoSil, fibrinogen in trombin, sta beljakovini, ki ju pridobivajo iz krvi, in ki sodelujeta pri naravnem procesu strjevanja krvi.
• during an operation, to stop bleeding and to seal the surfaces of internal organs; 
• pri kirurških posegih za zaustavitev krvavitve in za zapiranje površin notranjih organov;
• Two studies were carried out to see if TachoSil could be used as a tissue sealant. 
• Izvedeni sta bili dve študiji, da bi preverili, ali bi bilo mogoče zdravilo TachoSil uporabiti za zapiranje tkiva.
TachoSil must not be applied inside a blood vessel. 
Zdravilo TachoSil se ne sme uporabiti znotraj krvnih žil.
However, in the second study, which involved 301 patients, it took an average of 15.3 hours for leakage to stop with TachoSil compared with 20.5 hours with current techniques. 
Vendar pa je bil v drugi študiji, v kateri je sodeloval 301 bolnik, čas, potreben za zaustavitev puščanja, v povprečju 15,3 ure z zdravilom TachoSil v primerjavi z 20,5 ure pri standardnih tehnikah.
• Another study in 726 patients compared TachoSil with current techniques used in daily practice in preventing CSF leakage during neurological surgery. 
• V drugi študiji pri 726 bolnikih so zdravilo TachoSil primerjali s tehnikami, ki se trenutno uporabljajo v dnevni praksi preprečevanja prepuščanja cerebrospinalne tekočine pri nevrokirurških posegih.
The main measure of effectiveness was the time until the bleeding stopped. 
Glavno merilo učinkovitosti je bil čas, potreben za zaustavitev krvavitve.
• Two of the studies looked at the effects of TachoSil in stopping bleeding. 
• v dveh študijah so raziskovali vpliv zdravila TachoSil na zaustavitev krvavitve.
Like other sealants, TachoSil may cause an allergic reaction. 
Kot druga sredstva za zapiranje tkiva lahko tudi zdravilo TachoSil povzroči alergijske reakcije.
• during neurological surgery to prevent leakage of the fluid surrounding the brain (called cerebrospinal fluid or CSF). 
• pri nevrokirurških posegih za preprečevanje puščanja tekočine, ki obdaja možgane (imenovane cerebrospinalna tekočina).
Why has TachoSil been approved? 
Zakaj je bilo zdravilo TachoSil odobreno?
When TachoSil is applied to a bleeding area during surgery, the moisture causes the active substances to react together, leading to the rapid formation of a clot. 
Ko se zdravilo TachoSil med kirurškim posegom uporabi na območju krvavitve, vlaga povzroči, da zdravilni učinkovini reagirata skupaj, kar spodbudi hitrejše tvorjenje strdka.
For the full list of all side effects and restrictions with TachoSil, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila TachoSil glejte navodilo za uporabo.
TachoSil was also more effective than standard materials at stopping bleeding during surgery on the heart or blood vessels. 
Zdravilo TachoSil je bilo učinkovitejše od standardnih materialov pri zaustavljanju krvavitve med kirurškimi posegi na srcu ali krvnih žilah.
The clot enables the patch to stick more firmly to the tissue, helping to stop the bleeding and sealing the wound. 
Zaradi strdka se obliž lahko tesneje prilega tkivu, kar pomaga zaustaviti krvavitev in zapreti rano.
• A sixth study looked at the effectiveness of TachoSil in surgery on the heart or major blood vessels. 
• V šesti študiji so merili učinkovitost zdravila TachoSil pri kirurških posegih na srcu in glavnih krvnih žilah.
In the study in neurological surgery, TachoSil was comparable to current techniques: around 7% (25 out of 361) of patients treated with TachoSil had a leak of CSF, compared with around 8% (30 out of 365) of patients on current techniques. 
V študiji nevrokirurških posegov je bilo zdravilo TachoSil primerljiv s sedanjimi tehnikami: pri približno 7 % (25 od 361) bolnikov, zdravljenih z zdravilom TachoSil, je prišlo do prepuščanja cerebrospinalne tekočine, v primerjavi s približno 8 % (30 od 365) tistimi, ki so bili zdravljeni s sedanjimi tehnikami.
TachoSil is a sealant patch coated with the active substances human fibrinogen and human thrombin. 
Zdravilo TachoSil je obliž za zapiranje tkiva z zdravilnima učinkovinama humanim fibrinogenom in humanim trombinom.
The amount of TachoSil to be used depends on the size of the wound and the material can be cut to size if needed. 
Količina zdravila TachoSil je odvisna od velikosti rane.
The study compared TachoSil with standard materials in 120 patients, of whom around three-quarters also had surgery on vessels with stitches and one-quarter had surgery on the heart. 
V študiji so zdravilo TachoSil primerjali s standardnimi materiali pri 120 bolnikih, od katerih jih je približno 75 % imelo tudi kirurški poseg na ožilju s šivi, 25 % pa poseg na srcu.
After three minutes, bleeding had stopped in 75% of the patients treated with TachoSil (44 out of 59), compared with 33% of those treated with standard techniques (20 out of 60). 
(44 od 59), zdravljenih z zdravilom TachoSil, v primerjavi s 33 % (20 od 60) tistih, zdravljenih s standardnimi tehnikami.
• as support to stitching during surgery on the blood vessels; 
• kot pomoč pri šivanju pri kirurških posegih na ožilju;
Patients may also develop antibodies to the proteins in TachoSil, which could interfere with blood clotting. 
Za beljakovine zdravila TachoSil se lahko pri bolniku pojavijo protitelesa, ki lahko ovirajo strjevanje krvi.
Effectiveness was measured by looking at whether air leaked from the lungs after surgery. 
Merilo učinkovitosti je bilo, ali po kirurškem posegu iz pljuč uhaja zrak.
In neurological surgery, it works by sealing together the cut areas of the outermost layer (dura mater) of the membranes around the brain. 
Pri nevrokirurških posegih deluje tako, da zapre razrezana tkiva zunanje možganske ovojnice (dura mater).
What is TachoSil used for? 
Za kaj se zdravilo TachoSil uporablja?
How has TachoSil been studied? 
Kako je bilo zdravilo TachoSil raziskano?
What is TachoSil? 
Kaj je zdravilo TachoSil?
The studies compared the effects of TachoSil and an argon beamer (a device that sears the cut surface and reduces bleeding) in a total of 240 adults having liver surgery. 
V študijah pri 240 odraslih bolnikih, ki so imeli kirurški poseg na jetrih, so primerjali vpliv zdravila TachoSil in argonskega plazemskega koagulatorja (naprave, s katero termično koaguliramo porezano površino in zmanjšamo krvavenje).
How does TachoSil work? 
Kako zdravilo TachoSil deluje?
The studies compared TachoSil and standard surgical techniques, such as stitching and stapling, in a total of 490 patients having lung surgery. 
V študijah so pri 490 bolnikih, ki so imeli kirurški poseg na pljučih, primerjali zdravilo TachoSil in standardne kirurške tehnike, kot so šivanje in spenjanje.
A third study compared TachoSil with standard stitching in 185 patients having kidney surgery. 
V tretji študiji so pri 185 bolnikih, ki so imeli kirurški poseg na ledvicah, zdravilo TachoSil primerjali z običajnim šivanjem.
TachoSil was more effective than the argon beamer at stopping bleeding during liver surgery. 
Pri kirurškem posegu na jetrih je bilo v primerjavi z argonskim plazemskim koagulatorjem zdravilo TachoSil učinkovitejše pri zaustavljanju krvavitve.
How is TachoSil used? 
Kako se zdravilo TachoSil uporablja?
Thromboembolic complications (blood clots in vessels) may occur if TachoSil is applied inside a blood vessel. 
Če se zdravilo TachoSil nenamerno uporabi v krvni žili, lahko nastanejo tromboembolični zapleti (krvni strdki v žilah).
TachoSil was more effective than stitching in the kidney surgery patients. 
Pri bolnikih, ki so imeli kirurški poseg na ledvicah, je bilo zdravilo TachoSil bolj učinkovito kot šivanje.
This summary was last updated in 04-2008. 
Povzetek je bil nazadnje posodobljen 04-2008.
This helps to protect against the diseases that these bacteria and viruses cause. 
To pripomore k zaščiti pred boleznimi, ki jih povzročajo te bakterije in virusi.
The vaccine is ‘adsorbed'. 
Cepivo je „adsorbirano“.
The Hib component has also been available in other vaccines. 
Tudi sestavina proti Hib je bila na voljo v drugih cepivih.
This means that the active substances are fixed on aluminium compounds, to stimulate a better immune response. 
To pomeni, da so zdravilne učinkovine fiksirane na aluminijeve spojine za boljšo stimulacijo imunskega odziva.
Their breathing should be monitored for up to three days after vaccination. 
Pri teh otrocih je treba dihanje spremljati do tri dni po cepljenju.
In all of the studies, the main measure of effectiveness was the production of protective levels of antibodies after the final vaccination. 
V vseh študijah je bilo glavno merilo učinkovitosti nastanek zaščitnih ravni protiteles po opravljenem končnem cepljenju.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) QUINTANRIX EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) QUINTANRIX Povzetek EPAR za javnost
It should be used according to official recommendations. 
S cepivom cepimo v skladu z uradnimi priporočili.
The medicine can only be obtained with a prescription. 
Cepivo se dobi samo na recept.
The European Commission granted a marketing authorisation valid throughout the EU for Quintanrix to GlaxoSmithKline Biologicals s.a. on 21 October 2004. 
Evropska komisija je dovoljenje za promet s cepivom Quintanrix, veljavno po vsej Evropski uniji, odobrila družbi GlaxoSmithKline Biologicals s.a. dne 21. oktobra 2004.
The effects of Quintanrix have been studied in five main studies involving over 2,000 infants. 
Učinke cepiva Quintanrix so preučevali v petih glavnih študijah, v katere je bilo vključenih več kot 2000 dojenčkov.
It should not be given if the child has had encephalopathy (a brain disease) of unknown cause within seven days of a previous vaccination with a vaccine containing pertussis. 
Cepiva ne smejo prejeti otroci, ki so imeli encefalopatijo (bolezen možganov) neznanega vzroka v sedmih dneh po prejšnjem cepljenju s cepivom proti oslovskemu kašlju.
• killed whole B. pertussis; 
• uničene cele bakterije B. pertussis,
• ‘surface antigen' (proteins from the surface) of the hepatitis B virus. 
• „površinski antigen“ (beljakovino površine) virusa hepatitisa B.
These active substances were also available in other vaccines before that date. 
Te zdravilne učinkovine so bile še pred tem na voljo tudi v drugih cepivih.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘foreign' and makes antibodies against them. 
Ko otroka cepimo, imunski sistem prepozna dele bakterij in virusa kot „tuje“ in izdela protitelesa, usmerjena proti njim.
There was no impact of prior hepatitis B vaccination on the effectiveness of Quintanrix. 
Predhodno cepljenje proti hepatitisu B ni vplivalo na učinkovitost cepiva Quintanrix.
Quintanrix is a vaccine, which is available as a powder and suspension to be made up into a suspension for injection. 
Zdravilo Quintanrix je cepivo, ki je na voljo kot prašek in suspenzija, iz katerih se pripravi suspenzija za injiciranje.
The vaccine is given by deep injection into a muscle, preferably the thigh. 
Cepivo se daje z globokim injiciranjem v mišico, najboljše v stegno.
Quintanrix is a vaccine. 
Zdravilo Quintanrix je cepivo.
It is also used as a booster immunisation of young children during the second year of life. 
Uporablja se tudi za obnovitveno cepljenje otrok med drugim letom življenja.
• toxoids from the bacteria that cause diphtheria and tetanus; 
• toksoidov iz bakterij, ki povzročata davico in tetanus,
Other information about Quintanrix: 
Druge informacije o zdravilu Quintanrix:
The Committee recommended that Quintanrix be given marketing authorisation. 
Odbor je priporočil, da se za cepivo Quintanrix odobri dovoljenje za promet.
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology': they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins. 
Površinske antigene virusa hepatitisa B proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri kvasovka prejme gen (DNK), s katerim lahko tvori beljakovine.